Home・Aktien・Veracyte Inc

Veracyte Inc

Geschlossen

BrancheGesundheitswesen

46.18 3.52

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

43.07

Max

46.51

Schlüsselkennzahlen
By Trading Economics
Einkommen	-20M 29M
Verkäufe	-1.6M 139M
KGV Branchendurchschnitt	51.491 64.641
EPS	0.52
Gewinnspanne	20.642
Angestellte	755
EBITDA	-11M 35M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+27.34% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.8B 4.4B
Vorheriger Eröffnungskurs	42.66
Vorheriger Schlusskurs	46.18

Veracyte Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2026, 19:36 UTC

News

Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

3. Aug. 2026, 20:06 UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

1. Aug. 2026, 00:01 UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

31. Juli 2026, 20:02 UTC

News

Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

30. Juli 2026, 23:21 UTC

News

Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

29. Juli 2026, 19:47 UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

28. Juli 2026, 15:22 UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

27. Juli 2026, 20:14 UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

24. Juli 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22. Juli 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21. Juli 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20. Juli 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Peer-Vergleich

Kursveränderung

Veracyte Inc Prognose

Kursziel

By TipRanks

27.34% Vorteil

12-Monats-Prognose

Durchschnitt 57.11 USD 27.34%

Hoch 70 USD

Tief 44 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Veracyte Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Veracyte Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.